Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Nkarta, Inc. currently has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners, which suggests that the company is engaging with multiple reviewers for its current filings. The portfolio also spans 2 distinct art units, indicating that the pending applications cover different specialized areas within the biotechnology field. This distribution requires a strategy that can adapt to the different technical and procedural standards of two separate units. Managing 2 distinct art units involves navigating varied examination guidelines simultaneously.
The busiest examiner for Nkarta, Inc. is LIU, SUE XU, who is managing 1 busiest examiner pending action. Since there are 2 pending office actions in total, the workload is split between the 2 distinct examiners. This arrangement reduces the company's reliance on a single individual's review and provides feedback from two different technical perspectives. Navigating 2 distinct examiners and 2 distinct art units suggests that Nkarta, Inc. is pursuing a diversified intellectual property strategy within the pharmaceutical sector. Practitioners must tailor their responses to the specific technical requirements of both LIU, SUE XU and the other assigned examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| §112 only | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHUPE, ELIZABETH A | 1 | 66.2% | +44.2% |
| LIU, SUE XU | 1 | 20.9% | +18.6% |
| VAN BUREN, LAUREN K | 1 | 39.8% | +58.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18559514 | DOSING REGIMENS FOR CANCER IMMUNOTHERAPY | LIU, SUE XU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024012 | ENHANCED EXPANSION AND CYTOTOXICITY OF ENGINEERED NATURAL KILLER CELLS AND USES THEREOF | VAN BUREN, LAUREN K | 17d overdue |
| 18578164 | BCMA-DIRECTED CELLULAR IMMUNOTHERAPY COMPOSITIONS AND METHODS | SHUPE, ELIZABETH A | — |
| 18559514 | DOSING REGIMENS FOR CANCER IMMUNOTHERAPY | LIU, SUE XU | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578164 | BCMA-DIRECTED CELLULAR IMMUNOTHERAPY COMPOSITIONS AND METHODS | SHUPE, ELIZABETH A | — | §112 | Non-Final OA | — | Pending | Jan 10, 2024 |
| 18559514 | DOSING REGIMENS FOR CANCER IMMUNOTHERAPY | LIU, SUE XU | 1616 | §103Other | Non-Final OA | — | Pending | Nov 07, 2023 |
| 18024012 | ENHANCED EXPANSION AND CYTOTOXICITY OF ENGINEERED NATURAL KILLER CELLS AND USES THEREOF | VAN BUREN, LAUREN K | 1638 | §103 | Non-Final OA | 17d overdue | Pending | Feb 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial